NDANASALSPRAY, METERED
Approved
Mar 2023
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
11
Data completeness
4/8 — Partial
Drug data last refreshed 2h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ZAVZPRET is zavegepant, a small-molecule nasal spray approved by FDA in March 2023 for acute migraine treatment. It represents a novel non-triptan, non-CGRP mechanism delivered via intranasal metered spray, designed for rapid symptom relief in episodic migraine patients seeking alternatives to oral or injectable therapies.
$0.002BPart D
Peak7.8 years to LOEEarly-stage peak lifecycle with minimal Part D penetration signals a brand still building awareness and adoption; expect growth-focused teams with emphasis on field engagement and payer strategy.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (11)
Zavegepant Intranasal Spray for the Acute Treatment of Episodic Cluster Headache
Started Oct 2026
40 enrolled
Cluster Headache
A Study to Learn About Zavegepant as a Treatment for Multiple Migraine Attacks in Adult Participants
Started Sep 2025
0Migraine
A Study to Learn About the Study Medicine Called Zavegepant (PF-07930207) in Children With a History of Migraine
Started May 2025
16 enrolled
Acute Treatment of Migraine
A Study to Learn How the Study Medicine Called Zavegepant is Taken Up Into Blood and Breast Milk of Healthy Breast-Feeding Women
Started Jun 2024
12 enrolled
Healthy
A Study to Learn About Zavegepant as the Acute Treatment of Migraine in Asian Adults
Started Nov 2023
1,414 enrolled
Migraine
Worked on ZAVZPRET at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.